Comparison · NCT00636168-sae
IPILIMUMAB 10 MG/KG vs PLACEBO: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. IPILIMUMAB 10 MG/KG vs PLACEBO: serious adverse events. Trial comparisons, record NCT00636168-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00636168-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.546 | 0.5 | 0.59 | wilson | |
| Risk in group 2 | 0.27 | 0.232 | 0.312 | wilson | |
| Risk difference, group 1 minus group 2 | 0.276 | 0.214 | 0.334 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.02 | 1.71 | 2.39 | log | |
| Odds ratio, group 1 over group 2 | 3.25 | 2.47 | 4.26 | log | |
| Number needed to harm, for one more participant with a serious adverse event on IPILIMUMAB 10 MG/KG than on PLACEBO | 3.63 | 2.99 | 4.67 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | IPILIMUMAB 10 MG/KG | 257 | 471 | EG000 | |
| Group 2 | PLACEBO | 128 | 474 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Day 1 up to 70 days after last dose. Up to 10 years.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
- NCT number
- NCT00636168
- Phases
- PHASE3
- Conditions
- High Risk Stage III Melanoma
- Interventions
- ipilimumab, Placebo
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2014-08-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00636168?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00636168-sae